Literature DB >> 27554629

Steven Johnson Syndrome and Toxic Epidermal Necrolysis in a burn unit: A 15-year experience.

M McCullough1, M Burg2, E Lin2, D Peng3, W Garner2.   

Abstract

INTRODUCTION: The diffuse epidermal exfoliation seen in Steven Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) is similar to skin loss in second degree burns, and many of these patients are referred for treatment at burn centers. Treatment can differ markedly from center to center, and mortality can range from 25% to 70%, including a considerable morbidity. However, our experience over a 15-year period from 2000 to 2015 with 40 patients found a mortality rate of only 10% (4/40). The purpose of this paper is to discuss our treatment algorithm as a model for other centers treating SJS/TENs patients.
METHODS: Records were reviewed for all patients admitted to the LAC+USC burn unit between 2000 and 2015 and 40 patients were identified with biopsy-proven SJS or TENS. These cases were reviewed for age, gender, initial and greatest TBSA, causative drug, pre-existing medical conditions, and morbidity and mortality. All data were entered into the SPSS statistical software package and all statistical analyses were performed using this program.
RESULTS: Our treatment algorithm focused on early referral to a specialty burn unit, immediate discontinuation of the offending drug, fluid resuscitation, nutritional supplementation, and meticulous wound care. Average time to transfer to a burn unit was 3.36 days. Silver-releasing antimicrobial dressings were applied to the affected skin surface and changed every 3 days. Mupirocin coated petroleum gauze was used for facial involvement. Steroids were tapered and discontinued if initiated at an outside facility (58% of patients), and starting after 2001, all patients received a course of IVIG. All patients received fluid resuscitation and the majority received supplemental tube feedings (69%). Average length of total stay was 17.1 days and length of ICU stay 15.9 days. While 44% were transferred to another facility for further rehabilitative care, 37% of patients discharge to home. In patients discharged home with complete resolution of skin lesions, time to healing was an average of 14 days. DISCUSSION: With our 10% mortality rate in 40 patients, our study represents a relatively large study population while maintaining a relatively low mortality rate. The demographic data from our study largely aligns with the existing literature, and we therefore feel that our low mortality rate is due to our treatment algorithm, rather than to a less severe pathology in our patient population. This claim is supported by a standard mortality ratio of 1.68. This ratio proves a significantly improved mortality than would be expected based on disease severity on admission.
Copyright © 2016 Elsevier Ltd and ISBI. All rights reserved.

Entities:  

Keywords:  Steven Johnson Syndrome; Toxic Epidermal Necrolysis

Mesh:

Substances:

Year:  2016        PMID: 27554629     DOI: 10.1016/j.burns.2016.07.026

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  12 in total

1.  Drug Hypersensitivity Reactions Documented in Electronic Health Records within a Large Health System.

Authors:  Adrian Wong; Diane L Seger; Kenneth H Lai; Foster R Goss; Kimberly G Blumenthal; Li Zhou
Journal:  J Allergy Clin Immunol Pract       Date:  2018-12-01

2.  Treatment of severe drug reactions by hemodialysis.

Authors:  Rokea A El-Azhary; Michael Z Wang; Ashley B Wentworth; LaTonya J Hickson
Journal:  Int J Dermatol       Date:  2017-11-22       Impact factor: 2.736

Review 3.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

4.  Inpatient Mortality Resulting from Dermatological Disorders at a Tertiary Care Center in Eastern India: A Record-based Observational Study.

Authors:  Satyendranath Chowdhury; Indrashis Podder; Abanti Saha; Debabrata Bandyopadhyay
Journal:  Indian J Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.494

5.  Oseltamivir induced Stevens-Johnson syndrome/toxic epidermal necrolysis-case report.

Authors:  Wei Zuo; Li-Ping Wen; Jun Li; Dan Mei; Qiang Fu; Bo Zhang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

6.  Impact of Antibiotics Associated with the Development of Toxic Epidermal Necrolysis on Early and Late-Onset Infectious Complications.

Authors:  Bretislav Lipovy; Jakub Holoubek; Marketa Hanslianova; Michaela Cvanova; Leo Klein; Ivana Grossova; Robert Zajicek; Peter Bukovcan; Jan Koller; Matus Baran; Peter Lengyel; Lukas Eimer; Marie Jandova; Milan Kostal; Pavel Brychta; Petra Borilova Linhartova
Journal:  Microorganisms       Date:  2021-01-19

7.  Autologous scalp skin grafting to treat toxic epidermal necrolysis in a patient with a large skin injury: A case report.

Authors:  Dong-Dong Xue; Ling Zhou; Yong Yang; Si-Yuan Ma
Journal:  World J Clin Cases       Date:  2021-03-06       Impact factor: 1.337

8.  Case Report: Wound Closure Acceleration in a Patient With Toxic Epidermal Necrolysis Using a Lyophilised Amniotic Membrane.

Authors:  Bretislav Lipový; Martin Hladík; Petr Štourač; Serhiy Forostyak
Journal:  Front Bioeng Biotechnol       Date:  2021-04-16

9.  Recurrent Steven-Johnson/Toxic Epidermal Necrolysis Overlap Syndrome.

Authors:  Juan F Toledo-Martinez; Ethel V Galdamez-Carcamo; Francisco J Somoza-Cano; Diego A Padilla-Mantilla; Karina L Alvarenga-Alvarado
Journal:  Cureus       Date:  2022-01-18

10.  Intravenous Immunoglobulin Combined With Corticosteroids for the Treatment of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Propensity-Matched Retrospective Study in China.

Authors:  Lu Yang; Yan-Hong Shou; Feng Li; Xiao-Hua Zhu; Yong-Sheng Yang; Jin-Hua Xu
Journal:  Front Pharmacol       Date:  2022-01-18       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.